Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects

1. The aim of the study was to evaluate the pharmacokinetics of peramivir after single intravenous (i.v.) doses in healthy Chinese subjects.2. In a cross-over study, 12 subjects were given 300 and 600 mg peramivir by i.v. infusion. Blood and urine samples were collected at 17 designated time points and 7 designated intervals up to 36 h post-dose. Plasma and urine concentrations of peramivir were quantified by LC-MS/MS.3. After single i.v. doses of 300 and 600 mg peramivir, Cmax and AUC0–t of peramivir were 21.4 ± 3.7, 41.1 ± 5.3 mgċL−1 and 55.90 ± 10.62, 112.1 ± 13.2 mgċh L−1, respectively. Cmax and AUC increased in proportion to the dose. Within 12 h, accumulative urinary recoveries of peramivir after single i.v. doses of 300 and 600 mg peramivir were 84.31 ± 11.75% and 88.10 ± 7.39%, respectively.4. In healthy Chinese subjects, peramivir displayed linear pharmacokinetics in the range of 300–600 mg, and was primarily excreted via urine as unchanged drug.